{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-058863","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.331131+00:00","generated_at":"2026-05-23T05:54:26.210971+00:00","sec_items":["2.05","3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Spruce Biosciences cuts 55% workforce; Nasdaq to delist stock on April 29","bullets":["Workforce reduction of 55% approved by Board; estimated $0.9M cash charges in Q2 2025.","Reduction prioritizes development of tralesinidase alfa for Sanfilippo Syndrome Type B.","Nasdaq delisting notice received April 22; trading suspended at open on April 29, 2025.","Stock expected to trade OTC under SPRB; appealing to Hearings Panel; seeking reverse stock split at annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-058863","json":"https://secwatch.observer/filing/0000950170-25-058863.json","markdown":"https://secwatch.observer/filing/0000950170-25-058863.md","text":"https://secwatch.observer/filing/0000950170-25-058863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025058863/0000950170-25-058863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025058863/sprb-20250421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:54:26.210971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b2d9fcdddcbb540015af347725b79fb9fdc283d","claim":"SPRUCE BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5815(a)(1)(B)(ii)(d), 5810(c)(3)(A)(ii), 5800).","evidence_excerpt":"pects that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company has appealed Nasdaq’s determination to its Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. However, pursuant to Nasdaq Listing Rule 5815(a)(1)(B)(ii)(d), a timely request for a hearing will not stay the trading suspension of the Company’s common stock as the Company was afforded the second 180 days compliance period described in Nasdaq Listing Rule 5810(c)(3)(A)(ii) and","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025058863/0000950170-25-058863-index.htm","confidence":0.82,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5815(a)(1)(B)(ii)(d), 5810(c)(3)(A)(ii), 5800"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"96f80b7cb4414627cb721927761a4e7efd8de85a","claim":"SPRUCE BIOSCIENCES, INC. announced a restructuring with charges of approximately $0.9 million (workforce reduction of 55%).","evidence_excerpt":"and expenditures relating to the workforce reduction will not be known until all related activities have been completed. The Company estimates that it will incur approximately $0.9 million in cash charges in connection with the workforce reduction, consisting of expenses related to severance payments and healthcare coverage assistance and related costs. The Company","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017025058863/0000950170-25-058863-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.9 million"},{"label":"Headcount","value":"workforce reduction of 55%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}